BANGALORE, Aug 19 (Reuters) - Myriad Genetics Inc posted a wider-than-expected quarterly loss, excluding a one-time licensing gain and other costs, and said it is considering strategic options that includes a possible separation of its molecular diagnostic business from its pharmaceutical business.
